CL2016003191A1 - Polipéptidos receptores formulados y métodos relacionados - Google Patents

Polipéptidos receptores formulados y métodos relacionados

Info

Publication number
CL2016003191A1
CL2016003191A1 CL2016003191A CL2016003191A CL2016003191A1 CL 2016003191 A1 CL2016003191 A1 CL 2016003191A1 CL 2016003191 A CL2016003191 A CL 2016003191A CL 2016003191 A CL2016003191 A CL 2016003191A CL 2016003191 A1 CL2016003191 A1 CL 2016003191A1
Authority
CL
Chile
Prior art keywords
formulated
related methods
receptor polypeptides
protein
composition
Prior art date
Application number
CL2016003191A
Other languages
English (en)
Inventor
Michael Haqq Christopher
Latypov Ramil
Original Assignee
Santa Maria Biotherapeutics Inc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Maria Biotherapeutics Inc, Amgen Inc filed Critical Santa Maria Biotherapeutics Inc
Publication of CL2016003191A1 publication Critical patent/CL2016003191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>Composición que comprende una solución de proteína, donde la proteína se selecciona de un polipéptido capaz de unirse a miostatina, activina A o GDF-11; método de producción de la proteína; y uso de la composición para inhibir el crecimiento de un tumor sólido.</p>
CL2016003191A 2014-06-13 2016-12-13 Polipéptidos receptores formulados y métodos relacionados CL2016003191A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462012104P 2014-06-13 2014-06-13
US201462047995P 2014-09-09 2014-09-09
US201462058789P 2014-10-02 2014-10-02
US201562142812P 2015-04-03 2015-04-03

Publications (1)

Publication Number Publication Date
CL2016003191A1 true CL2016003191A1 (es) 2017-11-10

Family

ID=54834575

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003191A CL2016003191A1 (es) 2014-06-13 2016-12-13 Polipéptidos receptores formulados y métodos relacionados

Country Status (19)

Country Link
US (2) US20170202909A1 (es)
EP (1) EP3155008B1 (es)
JP (1) JP2017519009A (es)
KR (1) KR20170035891A (es)
CN (1) CN107074931A (es)
AP (1) AP2016009647A0 (es)
AU (1) AU2015274293A1 (es)
BR (1) BR112016029211A2 (es)
CA (1) CA2952231A1 (es)
CL (1) CL2016003191A1 (es)
EA (1) EA201692568A1 (es)
IL (1) IL249373A0 (es)
MX (1) MX2016016281A (es)
PE (1) PE20170471A1 (es)
PH (1) PH12016502479A1 (es)
SG (1) SG11201610432UA (es)
TN (1) TN2016000551A1 (es)
TW (1) TW201625675A (es)
WO (1) WO2015192127A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00380B (me) 2005-11-23 2011-10-10 Acceleron Pharma Inc Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US9526759B2 (en) 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR101672156B1 (ko) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
MX385318B (es) 2009-06-08 2025-03-18 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
DK3286206T3 (da) 2015-04-22 2021-05-03 Biogen Ma Inc Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme
US20170240639A1 (en) * 2016-02-22 2017-08-24 Acceleron Pharma Inc. Actrii antagonists for use in increasing immune activity
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN111278453A (zh) * 2017-09-07 2020-06-12 Jcr制药股份有限公司 水性药物组合物
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
KR20250059538A (ko) 2017-11-09 2025-05-02 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
JP7510875B2 (ja) 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
AU2019333042B2 (en) * 2018-08-29 2025-06-19 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
WO2020074691A1 (en) * 2018-10-12 2020-04-16 Advanced Accelerator Applications International Sa Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
BR112022016470A2 (pt) * 2020-02-21 2022-11-22 Spitfire Pharma Llc Formulação de dosagem farmacêutica, e, métodos para diminuir a glicemia de um mamífero e para induzir perda de peso em um mamífero
KR20230004515A (ko) 2020-03-20 2023-01-06 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
ATE362534T2 (de) 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
JP4038118B2 (ja) 2002-11-29 2008-01-23 株式会社コガネイ 流体圧シリンダ
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
TW201718635A (zh) * 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
BRPI0907186A2 (pt) * 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
KR20170105124A (ko) * 2008-11-26 2017-09-18 암젠 인크 액티빈 ｉｉｂ 수용체 폴리펩타이드의 변이체 및 이의 용도
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
AU2014212014A1 (en) * 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2016205370A1 (en) * 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins

Also Published As

Publication number Publication date
JP2017519009A (ja) 2017-07-13
EP3155008A4 (en) 2018-05-16
AU2015274293A1 (en) 2017-02-02
EP3155008B1 (en) 2020-08-26
BR112016029211A2 (pt) 2018-01-30
SG11201610432UA (en) 2017-01-27
EA201692568A1 (ru) 2017-05-31
CN107074931A (zh) 2017-08-18
PH12016502479A1 (en) 2017-04-10
WO2015192127A2 (en) 2015-12-17
AP2016009647A0 (en) 2016-12-31
KR20170035891A (ko) 2017-03-31
TW201625675A (zh) 2016-07-16
US20240277805A1 (en) 2024-08-22
WO2015192127A3 (en) 2016-03-17
MX2016016281A (es) 2017-03-31
EP3155008A2 (en) 2017-04-19
PE20170471A1 (es) 2017-05-14
CA2952231A1 (en) 2015-12-17
IL249373A0 (en) 2017-02-28
US20170202909A1 (en) 2017-07-20
TN2016000551A1 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
CL2016003191A1 (es) Polipéptidos receptores formulados y métodos relacionados
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX2018003491A (es) Represores de htt y usos de estos.
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
DK3121175T3 (da) 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
CL2016001911A1 (es) Compuesto heterocíclico fusionado
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2019000641A (es) Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
ECSP17027755A (es) Síntesis de copanlisib y su sal diclorhidrato
MX373268B (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
MX384427B (es) Composiciones de proteína concentrada y métodos para su elaboración y uso.
MX377774B (es) Formulaciones de proteinas.
MX394086B (es) Composiciones de cemento de vida útil prolongada que comprenden sólidos de lodo rojo.
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
MX2020004512A (es) Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos.